Candel Therapeutics Downgraded to Neutral by B of A Securities
PorAinvest
miércoles, 3 de septiembre de 2025, 12:02 pm ET1 min de lectura
CADL--
The downgrade comes after Candel Therapeutics reported earnings of ($0.09) per share for its last quarter, which outperformed analysts' expectations of ($0.17). Despite this positive earnings performance, the company has been grappling with a consensus rating of "Buy" from five research firms, with a 12-month average target price of $22.00 [1].
The decision by Bank of America Securities to downgrade the stock to "Neutral" is likely influenced by several factors. One key consideration is the company's ongoing clinical trials for its lead viral immunotherapy candidate, CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for prostate cancer, and Phase II clinical trials for lung cancer [2].
Institutional investors have shown growing interest in Candel Therapeutics, with several prominent firms increasing their stakes in the company. However, the company's market capitalization of $317.87 million and a debt-to-equity ratio of 0.01 suggest a relatively stable financial position [1].
The appointment of Carl H. June, M.D., to Candel's Research Advisory Board in August 2025 also signals a strategic move to advance the company's lead product candidate, CAN-2409, across multiple solid tumor indications [2]. Dr. June, a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, brings valuable expertise to the company.
Despite the downgrade, Candel Therapeutics continues to face significant challenges in its clinical trials and market penetration. The company's ability to successfully navigate these challenges and achieve regulatory approvals will be crucial for its long-term success.
References:
[1] https://www.marketbeat.com/instant-alerts/candel-therapeutics-inc-nasdaqcadl-receives-consensus-rating-of-buy-from-brokerages-2025-08-30/
[2] https://www.biospace.com/press-releases/candel-therapeutics-appoints-renowned-immunotherapy-pioneer-carl-h-june-m-d-to-research-advisory-board
Candel Therapeutics Downgraded to Neutral by B of A Securities
Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical-stage biopharmaceutical company, has faced a significant change in its stock rating. On September 2, 2025, Bank of America Securities downgraded the company's stock to a "Neutral" rating, reflecting a shift in the investment outlook [1].The downgrade comes after Candel Therapeutics reported earnings of ($0.09) per share for its last quarter, which outperformed analysts' expectations of ($0.17). Despite this positive earnings performance, the company has been grappling with a consensus rating of "Buy" from five research firms, with a 12-month average target price of $22.00 [1].
The decision by Bank of America Securities to downgrade the stock to "Neutral" is likely influenced by several factors. One key consideration is the company's ongoing clinical trials for its lead viral immunotherapy candidate, CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for prostate cancer, and Phase II clinical trials for lung cancer [2].
Institutional investors have shown growing interest in Candel Therapeutics, with several prominent firms increasing their stakes in the company. However, the company's market capitalization of $317.87 million and a debt-to-equity ratio of 0.01 suggest a relatively stable financial position [1].
The appointment of Carl H. June, M.D., to Candel's Research Advisory Board in August 2025 also signals a strategic move to advance the company's lead product candidate, CAN-2409, across multiple solid tumor indications [2]. Dr. June, a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, brings valuable expertise to the company.
Despite the downgrade, Candel Therapeutics continues to face significant challenges in its clinical trials and market penetration. The company's ability to successfully navigate these challenges and achieve regulatory approvals will be crucial for its long-term success.
References:
[1] https://www.marketbeat.com/instant-alerts/candel-therapeutics-inc-nasdaqcadl-receives-consensus-rating-of-buy-from-brokerages-2025-08-30/
[2] https://www.biospace.com/press-releases/candel-therapeutics-appoints-renowned-immunotherapy-pioneer-carl-h-june-m-d-to-research-advisory-board
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios